Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 5/20 | 0.63 |
| ▸ | NPY1R | P25929 | 3/20 | 0.60 |
| ▸ | NPY2R | P49146 | 3/20 | 0.60 |
| ▸ | NPY4R | P50391 | 3/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.59 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.57 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.57 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.57 |
| ▸ | IL1RN | P18510 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31731732 | 0.99 | GHSR (0.62) | GHSRNPY1RNPY2RNPY4ROPRM1 | |
| SCHEMBL29425246 | 0.97 | GHSR (0.60) | GHSRNPY1RNPY2RNPY4ROPRM1 | |
| SCHEMBL29508714 | 0.97 | GHSR (0.64) | GHSRNPY1RNPY2RNPY4ROPRM1 | |
| SCHEMBL29896929 | 0.96 | GHSR (0.63) | GHSRNPY1RNPY2RNPY4ROPRM1 | |
| SCHEMBL29577431 | 0.96 | NPY1R (0.66) | GHSRNPY1RNPY2RNPY4RERAP2 | |
| SCHEMBL29578675 | 0.96 | NPY1R (0.66) | GHSRNPY1RNPY2RNPY4RERAP2 | |
| SCHEMBL29508679 | 0.95 | GHSR (0.64) | GHSRNPY1RNPY2RNPY4RERAP2 | |
| SCHEMBL30633854 | 0.95 | GHSR (0.67) | GHSR | |
| SCHEMBL30437922 | 0.94 | GHSR (0.66) | GHSR | |
| SCHEMBL30169433 | 0.94 | GHSR (0.68) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389057-A1 | ENDOCYTOSIS ROUTING SEQUENCE PEPTIDE FOR CELL DELIVERY SYSTEMS | SZTE TTC ZÁRTKÖRUEN MUKÖDO RÉSZVÉNYTÁRSASÁG (HU) | 2022-12-08 | — | — | US | claimed |
| EP-3980439-A1 | ENDOCYTOSIS ROUTING SEQUENCE PEPTIDE FOR CELL DELIVERY SYSTEMS | Szegedi Tudományegyetem (HU) | 2022-04-13 | — | — | EP | claimed |
| EP-4439060-B1 | METHOD FOR CORRELATING MASS SPECTROMETER DATA WITH RESOLVED ANALYTE PEAK | INTABIO LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250003922-A1 | SOFTWARE FOR MICROFLUIDIC SYSTEMS INTERFACING WITH MASS SPECTROMETRY | INTABIO LLC (US) | 2025-01-02 | — | — | US | disclosed |
| US-12174144-B2 | Software for microfluidic systems interfacing with mass spectrometry | INTABIO, LLC (US) | 2024-12-24 | — | — | US | disclosed |
| US-20240377359-A1 | SOFTWARE FOR MICROFLUIDIC SYSTEMS INTERFACING WITH MASS SPECTROMETRY | INTABIO LLC (US) | 2024-11-14 | — | — | US | disclosed |
| EP-4439060-A2 | SOFTWARE FOR MICROFLUIDIC SYSTEMS INTERFACING WITH MASS SPECTROMETRY | INTABIO, LLC (US) | 2024-10-02 | — | — | EP | disclosed |
| EP-3811397-B1 | METHODS FOR INTERFACING MICROFLUIDIC SYSTEMS WITH MASS SPECTROMETRY | INTABIO LLC (US) | 2024-09-18 | — | — | EP | disclosed |
| EP-4413380-A1 | SOFTWARE FOR MICROFLUIDIC SYSTEMS INTERFACING WITH MASS SPECTROMETRY | Intabio, LLC (US) | 2024-08-14 | — | — | EP | disclosed |
| US-20230417703-A1 | SOFTWARE FOR MICROFLUIDIC SYSTEMS INTERFACING WITH MASS SPECTROMETRY | INTABIO, LLC | 2023-12-28 | — | — | US | disclosed |
| CN-116457028-A | Novel CXCR4 targeting compounds | 省卫生服务机构 | 2023-07-18 | — | — | CN | disclosed |
| US-20230176009-A1 | SOFTWARE FOR MICROFLUIDIC SYSTEMS INTERFACING WITH MASS SPECTROMETRY | INTABIO, LLC | 2023-06-08 | — | — | US | disclosed |
| WO-2023059595-A1 | SOFTWARE FOR MICROFLUIDIC SYSTEMS INTERFACING WITH MASS SPECTROMETRY | INTABIO, LLC (US) | 2023-04-13 | — | — | WO | disclosed |
| US-20230010104-A1 | SOFTWARE FOR MICROFLUIDIC SYSTEMS INTERFACING WITH MASS SPECTROMETRY | INTABIO LLC (US) | 2023-01-12 | — | — | US | disclosed |
| US-11541099-B2 | Flounder surimi having antioxidant and antihypertensive effects and method of preparing the same | JEJU NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2023-01-03 | — | — | US | disclosed |
| US-20220389057-A1 | ENDOCYTOSIS ROUTING SEQUENCE PEPTIDE FOR CELL DELIVERY SYSTEMS | SZTE TTC ZÁRTKÖRUEN MUKÖDO RÉSZVÉNYTÁRSASÁG (HU) | 2022-12-08 | — | — | US | disclosed |
| EP-4065985-A1 | SOFTWARE FOR MICROFLUIDIC SYSTEMS INTERFACING WITH MASS SPECTROMETRY | Intabio, LLC (US) | 2022-10-05 | — | — | EP | disclosed |
| EP-3980439-A1 | ENDOCYTOSIS ROUTING SEQUENCE PEPTIDE FOR CELL DELIVERY SYSTEMS | Szegedi Tudományegyetem (HU) | 2022-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389057-A1 | ENDOCYTOSIS ROUTING SEQUENCE PEPTIDE FOR CELL DELIVERY SYSTEMS | MARCKS, SORT1, PICALM | GHSR 1240/4885NPY1R 559/4885NPY2R 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.